nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyl aminolevulinate—Aminolevulinic acid—ALAD—kidney cancer	0.0393	1	CrCbGaD
Methyl aminolevulinate—FCGR1A—Role of phospholipids in phagocytosis—ITPR2—kidney cancer	0.0251	0.0912	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cross-presentation of soluble exogenous antigens (endosomes)—PSMD7—kidney cancer	0.0125	0.0454	CbGpPWpGaD
Methyl aminolevulinate—Macular oedema—Paclitaxel—kidney cancer	0.0123	0.0179	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Class I MHC mediated antigen processing & presentation—ASB15—kidney cancer	0.0112	0.0407	CbGpPWpGaD
Methyl aminolevulinate—Eyelid oedema—Everolimus—kidney cancer	0.0106	0.0154	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Fcgamma receptor (FCGR) dependent phagocytosis—ITPR2—kidney cancer	0.00979	0.0356	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Regulation of actin dynamics for phagocytic cup formation—PAK1—kidney cancer	0.00976	0.0355	CbGpPWpGaD
Methyl aminolevulinate—Localized exfoliation—Capecitabine—kidney cancer	0.00912	0.0133	CcSEcCtD
Methyl aminolevulinate—Rash pustular—Temsirolimus—kidney cancer	0.00899	0.0131	CcSEcCtD
Methyl aminolevulinate—Eyelid oedema—Sunitinib—kidney cancer	0.00882	0.0129	CcSEcCtD
Methyl aminolevulinate—Skin ulcer—Pazopanib—kidney cancer	0.00867	0.0126	CcSEcCtD
Methyl aminolevulinate—Skin hyperpigmentation—Erlotinib—kidney cancer	0.00865	0.0126	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Class I MHC mediated antigen processing & presentation—CUL7—kidney cancer	0.00847	0.0308	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Antigen processing-Cross presentation—PSMD7—kidney cancer	0.00829	0.0302	CbGpPWpGaD
Methyl aminolevulinate—Keratitis—Erlotinib—kidney cancer	0.00793	0.0116	CcSEcCtD
Methyl aminolevulinate—Scab—Capecitabine—kidney cancer	0.00772	0.0113	CcSEcCtD
Methyl aminolevulinate—Skin hyperpigmentation—Sunitinib—kidney cancer	0.00749	0.0109	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Fcgamma receptor (FCGR) dependent phagocytosis—PAK1—kidney cancer	0.00736	0.0268	CbGpPWpGaD
Methyl aminolevulinate—Blister—Erlotinib—kidney cancer	0.00714	0.0104	CcSEcCtD
Methyl aminolevulinate—Rash pustular—Erlotinib—kidney cancer	0.00645	0.0094	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Pazopanib—kidney cancer	0.00645	0.0094	CcSEcCtD
Methyl aminolevulinate—Blister—Sunitinib—kidney cancer	0.00618	0.00901	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Class I MHC mediated antigen processing & presentation—VHL—kidney cancer	0.00613	0.0223	CbGpPWpGaD
Methyl aminolevulinate—Swelling—Temsirolimus—kidney cancer	0.0059	0.0086	CcSEcCtD
Methyl aminolevulinate—Eczema—Temsirolimus—kidney cancer	0.00579	0.00844	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—ASB15—kidney cancer	0.00553	0.0201	CbGpPWpGaD
Methyl aminolevulinate—Dermatitis bullous—Temsirolimus—kidney cancer	0.00544	0.00794	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Class I MHC mediated antigen processing & presentation—TCEB2—kidney cancer	0.00537	0.0196	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Class I MHC mediated antigen processing & presentation—TCEB1—kidney cancer	0.00537	0.0196	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Class I MHC mediated antigen processing & presentation—KEAP1—kidney cancer	0.00513	0.0187	CbGpPWpGaD
Methyl aminolevulinate—Skin exfoliation—Everolimus—kidney cancer	0.00509	0.00742	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Role of phospholipids in phagocytosis—PIK3CA—kidney cancer	0.00505	0.0184	CbGpPWpGaD
Methyl aminolevulinate—Skin hyperpigmentation—Paclitaxel—kidney cancer	0.00503	0.00733	CcSEcCtD
Methyl aminolevulinate—Face oedema—Temsirolimus—kidney cancer	0.00502	0.00732	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Erlotinib—kidney cancer	0.00491	0.00716	CcSEcCtD
Methyl aminolevulinate—Face oedema—Pazopanib—kidney cancer	0.00473	0.0069	CcSEcCtD
Methyl aminolevulinate—Keratitis—Paclitaxel—kidney cancer	0.00461	0.00672	CcSEcCtD
Methyl aminolevulinate—Ulcer—Dactinomycin—kidney cancer	0.00446	0.0065	CcSEcCtD
Methyl aminolevulinate—Sensitisation—Doxorubicin—kidney cancer	0.00443	0.00646	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Sorafenib—kidney cancer	0.00442	0.00644	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Sunitinib—kidney cancer	0.00425	0.0062	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CUL7—kidney cancer	0.00419	0.0153	CbGpPWpGaD
Methyl aminolevulinate—Skin hyperpigmentation—Capecitabine—kidney cancer	0.00413	0.00602	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Interferon Signaling—IFNA1—kidney cancer	0.00399	0.0145	CbGpPWpGaD
Methyl aminolevulinate—Dermatitis bullous—Erlotinib—kidney cancer	0.00391	0.0057	CcSEcCtD
Methyl aminolevulinate—Photosensitivity reaction—Pazopanib—kidney cancer	0.00387	0.00564	CcSEcCtD
Methyl aminolevulinate—Skin ulcer—Paclitaxel—kidney cancer	0.00384	0.0056	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—SRMS—kidney cancer	0.00384	0.014	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Interferon Signaling—EGR1—kidney cancer	0.00382	0.0139	CbGpPWpGaD
Methyl aminolevulinate—Keratitis—Capecitabine—kidney cancer	0.00379	0.00552	CcSEcCtD
Methyl aminolevulinate—Ulcer—Gemcitabine—kidney cancer	0.00378	0.00551	CcSEcCtD
Methyl aminolevulinate—Eczema—Sorafenib—kidney cancer	0.00374	0.00545	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Interferon Signaling—IFNA2—kidney cancer	0.00371	0.0135	CbGpPWpGaD
Methyl aminolevulinate—Eczema—Sunitinib—kidney cancer	0.0036	0.00524	CcSEcCtD
Methyl aminolevulinate—Eye irritation—Paclitaxel—kidney cancer	0.0035	0.00511	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Gemcitabine—kidney cancer	0.00341	0.00497	CcSEcCtD
Methyl aminolevulinate—Blister—Capecitabine—kidney cancer	0.00341	0.00497	CcSEcCtD
Methyl aminolevulinate—Dermatitis bullous—Sunitinib—kidney cancer	0.00338	0.00493	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Temsirolimus—kidney cancer	0.00336	0.0049	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—ASB15—kidney cancer	0.00336	0.0122	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Class I MHC mediated antigen processing & presentation—PSMD7—kidney cancer	0.00331	0.012	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CD274—kidney cancer	0.00318	0.0116	CbGpPWpGaD
Methyl aminolevulinate—Eye disorder—Pazopanib—kidney cancer	0.00317	0.00462	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Regulation of actin dynamics for phagocytic cup formation—MAPK3—kidney cancer	0.00316	0.0115	CbGpPWpGaD
Methyl aminolevulinate—Skin ulcer—Capecitabine—kidney cancer	0.00315	0.0046	CcSEcCtD
Methyl aminolevulinate—Erythema—Temsirolimus—kidney cancer	0.00313	0.00457	CcSEcCtD
Methyl aminolevulinate—Face oedema—Sunitinib—kidney cancer	0.00312	0.00455	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—VHL—kidney cancer	0.00303	0.011	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—TXNIP—kidney cancer	0.00303	0.011	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Regulation of actin dynamics for phagocytic cup formation—MAPK1—kidney cancer	0.00301	0.011	CbGpPWpGaD
Methyl aminolevulinate—Erythema—Pazopanib—kidney cancer	0.00295	0.0043	CcSEcCtD
Methyl aminolevulinate—Eye irritation—Capecitabine—kidney cancer	0.00288	0.00419	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Paclitaxel—kidney cancer	0.00286	0.00416	CcSEcCtD
Methyl aminolevulinate—Dermatitis bullous—Gemcitabine—kidney cancer	0.00271	0.00396	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—IFNA1—kidney cancer	0.00266	0.00969	CbGpPWpGaD
Methyl aminolevulinate—Skin hyperpigmentation—Doxorubicin—kidney cancer	0.00266	0.00388	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—TCEB2—kidney cancer	0.00266	0.00968	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—TCEB1—kidney cancer	0.00266	0.00968	CbGpPWpGaD
Methyl aminolevulinate—Ulcer—Capecitabine—kidney cancer	0.0026	0.00378	CcSEcCtD
Methyl aminolevulinate—Oedema—Temsirolimus—kidney cancer	0.00256	0.00373	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—EGR1—kidney cancer	0.00255	0.00929	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CUL7—kidney cancer	0.00254	0.00926	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—KEAP1—kidney cancer	0.00254	0.00925	CbGpPWpGaD
Methyl aminolevulinate—Infection—Temsirolimus—kidney cancer	0.00254	0.0037	CcSEcCtD
Methyl aminolevulinate—Face oedema—Gemcitabine—kidney cancer	0.0025	0.00365	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Everolimus—kidney cancer	0.0025	0.00365	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—IFNA2—kidney cancer	0.00248	0.00902	CbGpPWpGaD
Methyl aminolevulinate—Swelling—Paclitaxel—kidney cancer	0.00246	0.00359	CcSEcCtD
Methyl aminolevulinate—Keratitis—Doxorubicin—kidney cancer	0.00244	0.00356	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Erlotinib—kidney cancer	0.00241	0.00352	CcSEcCtD
Methyl aminolevulinate—Oedema—Pazopanib—kidney cancer	0.00241	0.00351	CcSEcCtD
Methyl aminolevulinate—Eye pain—Paclitaxel—kidney cancer	0.00241	0.00351	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CASP2—kidney cancer	0.00239	0.00871	CbGpPWpGaD
Methyl aminolevulinate—Infection—Pazopanib—kidney cancer	0.00239	0.00349	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Fcgamma receptor (FCGR) dependent phagocytosis—MAPK3—kidney cancer	0.00239	0.00869	CbGpPWpGaD
Methyl aminolevulinate—Skin exfoliation—Capecitabine—kidney cancer	0.00234	0.00342	CcSEcCtD
Methyl aminolevulinate—Erythema—Everolimus—kidney cancer	0.00233	0.0034	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—SRMS—kidney cancer	0.00233	0.00847	CbGpPWpGaD
Methyl aminolevulinate—Burning sensation—Doxorubicin—kidney cancer	0.00228	0.00332	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Fcgamma receptor (FCGR) dependent phagocytosis—MAPK1—kidney cancer	0.00227	0.00827	CbGpPWpGaD
Methyl aminolevulinate—Erythema—Erlotinib—kidney cancer	0.00225	0.00328	CcSEcCtD
Methyl aminolevulinate—Fatigue—Temsirolimus—kidney cancer	0.0022	0.00321	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CD34—kidney cancer	0.0022	0.00802	CbGpPWpGaD
Methyl aminolevulinate—Blister—Doxorubicin—kidney cancer	0.0022	0.0032	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CARD11—kidney cancer	0.00219	0.00797	CbGpPWpGaD
Methyl aminolevulinate—Pain—Temsirolimus—kidney cancer	0.00219	0.00319	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Pazopanib—kidney cancer	0.00216	0.00315	CcSEcCtD
Methyl aminolevulinate—Photosensitivity reaction—Vincristine—kidney cancer	0.00216	0.00314	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CARD11—kidney cancer	0.0021	0.00765	CbGpPWpGaD
Methyl aminolevulinate—Eye disorder—Sunitinib—kidney cancer	0.00209	0.00305	CcSEcCtD
Methyl aminolevulinate—Fatigue—Pazopanib—kidney cancer	0.00208	0.00303	CcSEcCtD
Methyl aminolevulinate—Pain—Pazopanib—kidney cancer	0.00206	0.003	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—ITPR2—kidney cancer	0.00204	0.00741	CbGpPWpGaD
Methyl aminolevulinate—Skin ulcer—Doxorubicin—kidney cancer	0.00203	0.00296	CcSEcCtD
Methyl aminolevulinate—Erythema—Sorafenib—kidney cancer	0.00202	0.00295	CcSEcCtD
Methyl aminolevulinate—Swelling—Capecitabine—kidney cancer	0.00202	0.00295	CcSEcCtD
Methyl aminolevulinate—Rash pustular—Doxorubicin—kidney cancer	0.00198	0.00289	CcSEcCtD
Methyl aminolevulinate—Eye pain—Capecitabine—kidney cancer	0.00197	0.00288	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Fcgamma receptor (FCGR) dependent phagocytosis—PIK3CA—kidney cancer	0.00197	0.00718	CbGpPWpGaD
Methyl aminolevulinate—Discomfort—Vinblastine—kidney cancer	0.00197	0.00287	CcSEcCtD
Methyl aminolevulinate—Discomfort—Everolimus—kidney cancer	0.00196	0.00286	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—ITPR2—kidney cancer	0.00195	0.00711	CbGpPWpGaD
Methyl aminolevulinate—Stinging—Doxorubicin—kidney cancer	0.00195	0.00285	CcSEcCtD
Methyl aminolevulinate—Erythema—Sunitinib—kidney cancer	0.00195	0.00284	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—CD274—kidney cancer	0.00193	0.00702	CbGpPWpGaD
Methyl aminolevulinate—Oedema—Everolimus—kidney cancer	0.0019	0.00277	CcSEcCtD
Methyl aminolevulinate—Infection—Everolimus—kidney cancer	0.00189	0.00276	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Temsirolimus—kidney cancer	0.00188	0.00275	CcSEcCtD
Methyl aminolevulinate—Dermatitis bullous—Capecitabine—kidney cancer	0.00186	0.00272	CcSEcCtD
Methyl aminolevulinate—Erythema—Dactinomycin—kidney cancer	0.00184	0.00269	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—VHL—kidney cancer	0.00184	0.00669	CbGpPWpGaD
Methyl aminolevulinate—Oedema—Erlotinib—kidney cancer	0.00184	0.00268	CcSEcCtD
Methyl aminolevulinate—Asthenia—Temsirolimus—kidney cancer	0.00183	0.00267	CcSEcCtD
Methyl aminolevulinate—Infection—Erlotinib—kidney cancer	0.00182	0.00266	CcSEcCtD
Methyl aminolevulinate—Pruritus—Temsirolimus—kidney cancer	0.00181	0.00264	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CTSB—kidney cancer	0.00177	0.00643	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—TXNIP—kidney cancer	0.00176	0.00642	CbGpPWpGaD
Methyl aminolevulinate—Asthenia—Pazopanib—kidney cancer	0.00173	0.00252	CcSEcCtD
Methyl aminolevulinate—Face oedema—Capecitabine—kidney cancer	0.00172	0.00251	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Vinblastine—kidney cancer	0.00171	0.0025	CcSEcCtD
Methyl aminolevulinate—Photosensitivity reaction—Paclitaxel—kidney cancer	0.00171	0.0025	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Everolimus—kidney cancer	0.00171	0.00249	CcSEcCtD
Methyl aminolevulinate—Pruritus—Pazopanib—kidney cancer	0.0017	0.00248	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CTSB—kidney cancer	0.0017	0.00617	CbGpPWpGaD
Methyl aminolevulinate—Dizziness—Temsirolimus—kidney cancer	0.00169	0.00247	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CTSD—kidney cancer	0.00169	0.00614	CbGpPWpGaD
Methyl aminolevulinate—Ulcer—Doxorubicin—kidney cancer	0.00167	0.00244	CcSEcCtD
Methyl aminolevulinate—Infection—Sorafenib—kidney cancer	0.00164	0.00239	CcSEcCtD
Methyl aminolevulinate—Fatigue—Everolimus—kidney cancer	0.00164	0.00239	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—PSMD7—kidney cancer	0.00164	0.00596	CbGpPWpGaD
Methyl aminolevulinate—Pain—Vinblastine—kidney cancer	0.00163	0.00238	CcSEcCtD
Methyl aminolevulinate—Pain—Everolimus—kidney cancer	0.00163	0.00237	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—TCEB1—kidney cancer	0.00161	0.00587	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—TCEB2—kidney cancer	0.00161	0.00587	CbGpPWpGaD
Methyl aminolevulinate—Rash—Temsirolimus—kidney cancer	0.00161	0.00235	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Temsirolimus—kidney cancer	0.00161	0.00235	CcSEcCtD
Methyl aminolevulinate—Headache—Temsirolimus—kidney cancer	0.0016	0.00234	CcSEcCtD
Methyl aminolevulinate—Dizziness—Pazopanib—kidney cancer	0.00159	0.00232	CcSEcCtD
Methyl aminolevulinate—Oedema—Sunitinib—kidney cancer	0.00159	0.00232	CcSEcCtD
Methyl aminolevulinate—Fatigue—Erlotinib—kidney cancer	0.00158	0.00231	CcSEcCtD
Methyl aminolevulinate—Infection—Sunitinib—kidney cancer	0.00158	0.0023	CcSEcCtD
Methyl aminolevulinate—Pain—Erlotinib—kidney cancer	0.00157	0.00229	CcSEcCtD
Methyl aminolevulinate—Dermatitis contact—Doxorubicin—kidney cancer	0.00156	0.00228	CcSEcCtD
Methyl aminolevulinate—Erythema—Gemcitabine—kidney cancer	0.00156	0.00228	CcSEcCtD
Methyl aminolevulinate—Discomfort—Dactinomycin—kidney cancer	0.00155	0.00226	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—KEAP1—kidney cancer	0.00154	0.00561	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—PAK1—kidney cancer	0.00153	0.00557	CbGpPWpGaD
Methyl aminolevulinate—Rash—Pazopanib—kidney cancer	0.00152	0.00221	CcSEcCtD
Methyl aminolevulinate—Nausea—Temsirolimus—kidney cancer	0.00152	0.00221	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Pazopanib—kidney cancer	0.00152	0.00221	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Doxorubicin—kidney cancer	0.00151	0.0022	CcSEcCtD
Methyl aminolevulinate—Headache—Pazopanib—kidney cancer	0.00151	0.0022	CcSEcCtD
Methyl aminolevulinate—Oedema—Dactinomycin—kidney cancer	0.0015	0.00219	CcSEcCtD
Methyl aminolevulinate—Infection—Dactinomycin—kidney cancer	0.00149	0.00218	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—IFNA1—kidney cancer	0.00149	0.00544	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—PAK1—kidney cancer	0.00147	0.00535	CbGpPWpGaD
Methyl aminolevulinate—Nausea—Pazopanib—kidney cancer	0.00143	0.00209	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Sunitinib—kidney cancer	0.00143	0.00208	CcSEcCtD
Methyl aminolevulinate—Fatigue—Sorafenib—kidney cancer	0.00142	0.00208	CcSEcCtD
Methyl aminolevulinate—Pain—Sorafenib—kidney cancer	0.00141	0.00206	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Vinblastine—kidney cancer	0.00141	0.00205	CcSEcCtD
Methyl aminolevulinate—Photosensitivity reaction—Capecitabine—kidney cancer	0.00141	0.00205	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Paclitaxel—kidney cancer	0.0014	0.00205	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Everolimus—kidney cancer	0.0014	0.00204	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—CASP2—kidney cancer	0.00139	0.00507	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—IFNA2—kidney cancer	0.00139	0.00506	CbGpPWpGaD
Methyl aminolevulinate—Asthenia—Vinblastine—kidney cancer	0.00137	0.002	CcSEcCtD
Methyl aminolevulinate—Fatigue—Sunitinib—kidney cancer	0.00137	0.002	CcSEcCtD
Methyl aminolevulinate—Asthenia—Everolimus—kidney cancer	0.00136	0.00199	CcSEcCtD
Methyl aminolevulinate—Pain—Sunitinib—kidney cancer	0.00136	0.00198	CcSEcCtD
Methyl aminolevulinate—Pruritus—Everolimus—kidney cancer	0.00135	0.00196	CcSEcCtD
Methyl aminolevulinate—Oedema—Vincristine—kidney cancer	0.00134	0.00196	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—CD34—kidney cancer	0.00134	0.00486	CbGpPWpGaD
Methyl aminolevulinate—Infection—Vincristine—kidney cancer	0.00134	0.00195	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Interferon Signaling—MAPK3—kidney cancer	0.00133	0.00483	CbGpPWpGaD
Methyl aminolevulinate—Asthenia—Erlotinib—kidney cancer	0.00132	0.00192	CcSEcCtD
Methyl aminolevulinate—Discomfort—Gemcitabine—kidney cancer	0.00131	0.00192	CcSEcCtD
Methyl aminolevulinate—Urticaria—Sorafenib—kidney cancer	0.00131	0.00191	CcSEcCtD
Methyl aminolevulinate—Erythema—Paclitaxel—kidney cancer	0.00131	0.00191	CcSEcCtD
Methyl aminolevulinate—Pruritus—Erlotinib—kidney cancer	0.0013	0.00189	CcSEcCtD
Methyl aminolevulinate—Fatigue—Dactinomycin—kidney cancer	0.0013	0.00189	CcSEcCtD
Methyl aminolevulinate—Pain—Dactinomycin—kidney cancer	0.00129	0.00188	CcSEcCtD
Methyl aminolevulinate—Eczema—Doxorubicin—kidney cancer	0.00128	0.00186	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—CARD11—kidney cancer	0.00128	0.00464	CbGpPWpGaD
Methyl aminolevulinate—Oedema—Gemcitabine—kidney cancer	0.00127	0.00186	CcSEcCtD
Methyl aminolevulinate—Eye pain—Doxorubicin—kidney cancer	0.00127	0.00186	CcSEcCtD
Methyl aminolevulinate—Infection—Gemcitabine—kidney cancer	0.00127	0.00185	CcSEcCtD
Methyl aminolevulinate—Dizziness—Vinblastine—kidney cancer	0.00126	0.00184	CcSEcCtD
Methyl aminolevulinate—Dizziness—Everolimus—kidney cancer	0.00126	0.00183	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—RAF1—kidney cancer	0.00123	0.00447	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—RELA—kidney cancer	0.00122	0.00445	CbGpPWpGaD
Methyl aminolevulinate—Hypersensitivity—Sorafenib—kidney cancer	0.00122	0.00177	CcSEcCtD
Methyl aminolevulinate—Dizziness—Erlotinib—kidney cancer	0.00121	0.00177	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Vincristine—kidney cancer	0.00121	0.00176	CcSEcCtD
Methyl aminolevulinate—Dermatitis bullous—Doxorubicin—kidney cancer	0.0012	0.00175	CcSEcCtD
Methyl aminolevulinate—Rash—Everolimus—kidney cancer	0.0012	0.00175	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Everolimus—kidney cancer	0.0012	0.00175	CcSEcCtD
Methyl aminolevulinate—Headache—Vinblastine—kidney cancer	0.0012	0.00174	CcSEcCtD
Methyl aminolevulinate—Headache—Everolimus—kidney cancer	0.00119	0.00174	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—ITPR2—kidney cancer	0.00119	0.00431	CbGpPWpGaD
Methyl aminolevulinate—Asthenia—Sorafenib—kidney cancer	0.00118	0.00173	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Sunitinib—kidney cancer	0.00117	0.00171	CcSEcCtD
Methyl aminolevulinate—Pruritus—Sorafenib—kidney cancer	0.00117	0.0017	CcSEcCtD
Methyl aminolevulinate—Fatigue—Vincristine—kidney cancer	0.00116	0.00169	CcSEcCtD
Methyl aminolevulinate—Rash—Erlotinib—kidney cancer	0.00116	0.00169	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Erlotinib—kidney cancer	0.00116	0.00169	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Capecitabine—kidney cancer	0.00115	0.00168	CcSEcCtD
Methyl aminolevulinate—Headache—Erlotinib—kidney cancer	0.00115	0.00168	CcSEcCtD
Methyl aminolevulinate—Pain—Vincristine—kidney cancer	0.00115	0.00168	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Gemcitabine—kidney cancer	0.00114	0.00167	CcSEcCtD
Methyl aminolevulinate—Asthenia—Sunitinib—kidney cancer	0.00114	0.00166	CcSEcCtD
Methyl aminolevulinate—Nausea—Vinblastine—kidney cancer	0.00113	0.00165	CcSEcCtD
Methyl aminolevulinate—Nausea—Everolimus—kidney cancer	0.00113	0.00165	CcSEcCtD
Methyl aminolevulinate—Pruritus—Sunitinib—kidney cancer	0.00112	0.00164	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CD8A—kidney cancer	0.00112	0.00408	CbGpPWpGaD
Methyl aminolevulinate—Face oedema—Doxorubicin—kidney cancer	0.00111	0.00162	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Dactinomycin—kidney cancer	0.00111	0.00162	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—IL2—kidney cancer	0.0011	0.00401	CbGpPWpGaD
Methyl aminolevulinate—Discomfort—Paclitaxel—kidney cancer	0.0011	0.0016	CcSEcCtD
Methyl aminolevulinate—Fatigue—Gemcitabine—kidney cancer	0.0011	0.0016	CcSEcCtD
Methyl aminolevulinate—Dizziness—Sorafenib—kidney cancer	0.00109	0.00159	CcSEcCtD
Methyl aminolevulinate—Pain—Gemcitabine—kidney cancer	0.00109	0.00159	CcSEcCtD
Methyl aminolevulinate—Nausea—Erlotinib—kidney cancer	0.00109	0.00159	CcSEcCtD
Methyl aminolevulinate—Asthenia—Dactinomycin—kidney cancer	0.00108	0.00157	CcSEcCtD
Methyl aminolevulinate—Erythema—Capecitabine—kidney cancer	0.00107	0.00156	CcSEcCtD
Methyl aminolevulinate—Oedema—Paclitaxel—kidney cancer	0.00107	0.00156	CcSEcCtD
Methyl aminolevulinate—Infection—Paclitaxel—kidney cancer	0.00106	0.00155	CcSEcCtD
Methyl aminolevulinate—Dizziness—Sunitinib—kidney cancer	0.00105	0.00153	CcSEcCtD
Methyl aminolevulinate—Rash—Sorafenib—kidney cancer	0.00104	0.00152	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Sorafenib—kidney cancer	0.00104	0.00152	CcSEcCtD
Methyl aminolevulinate—Headache—Sorafenib—kidney cancer	0.00103	0.00151	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—CTSB—kidney cancer	0.00103	0.00374	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CTSD—kidney cancer	0.00102	0.00372	CbGpPWpGaD
Methyl aminolevulinate—Rash—Sunitinib—kidney cancer	0.001	0.00146	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Sunitinib—kidney cancer	0.001	0.00146	CcSEcCtD
Methyl aminolevulinate—Headache—Sunitinib—kidney cancer	0.000995	0.00145	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—TSC2—kidney cancer	0.000994	0.00362	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—PSMD7—kidney cancer	0.000993	0.00361	CbGpPWpGaD
Methyl aminolevulinate—Hypersensitivity—Vincristine—kidney cancer	0.00099	0.00144	CcSEcCtD
Methyl aminolevulinate—Nausea—Sorafenib—kidney cancer	0.000981	0.00143	CcSEcCtD
Methyl aminolevulinate—Asthenia—Vincristine—kidney cancer	0.000964	0.00141	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Paclitaxel—kidney cancer	0.000958	0.0014	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—TSC2—kidney cancer	0.000954	0.00347	CbGpPWpGaD
Methyl aminolevulinate—Rash—Dactinomycin—kidney cancer	0.000948	0.00138	CcSEcCtD
Methyl aminolevulinate—Nausea—Sunitinib—kidney cancer	0.000944	0.00138	CcSEcCtD
Methyl aminolevulinate—Fatigue—Paclitaxel—kidney cancer	0.00092	0.00134	CcSEcCtD
Methyl aminolevulinate—Asthenia—Gemcitabine—kidney cancer	0.000915	0.00133	CcSEcCtD
Methyl aminolevulinate—Pain—Paclitaxel—kidney cancer	0.000913	0.00133	CcSEcCtD
Methyl aminolevulinate—Photosensitivity reaction—Doxorubicin—kidney cancer	0.000906	0.00132	CcSEcCtD
Methyl aminolevulinate—Discomfort—Capecitabine—kidney cancer	0.000903	0.00132	CcSEcCtD
Methyl aminolevulinate—Pruritus—Gemcitabine—kidney cancer	0.000902	0.00131	CcSEcCtD
Methyl aminolevulinate—Nausea—Dactinomycin—kidney cancer	0.000893	0.0013	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—PAK1—kidney cancer	0.000892	0.00325	CbGpPWpGaD
Methyl aminolevulinate—Dizziness—Vincristine—kidney cancer	0.000889	0.0013	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—MAPK3—kidney cancer	0.000886	0.00322	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—KIT—kidney cancer	0.000878	0.00319	CbGpPWpGaD
Methyl aminolevulinate—Oedema—Capecitabine—kidney cancer	0.000876	0.00128	CcSEcCtD
Methyl aminolevulinate—Infection—Capecitabine—kidney cancer	0.00087	0.00127	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—IFNA1—kidney cancer	0.00087	0.00317	CbGpPWpGaD
Methyl aminolevulinate—Urticaria—Paclitaxel—kidney cancer	0.000848	0.00124	CcSEcCtD
Methyl aminolevulinate—Rash—Vincristine—kidney cancer	0.000847	0.00124	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Vincristine—kidney cancer	0.000847	0.00123	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—KIT—kidney cancer	0.000843	0.00307	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—MAPK1—kidney cancer	0.000843	0.00307	CbGpPWpGaD
Methyl aminolevulinate—Headache—Vincristine—kidney cancer	0.000842	0.00123	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—EGR1—kidney cancer	0.000834	0.00304	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—IFNA2—kidney cancer	0.00081	0.00295	CbGpPWpGaD
Methyl aminolevulinate—Rash—Gemcitabine—kidney cancer	0.000804	0.00117	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Gemcitabine—kidney cancer	0.000803	0.00117	CcSEcCtD
Methyl aminolevulinate—Headache—Gemcitabine—kidney cancer	0.000799	0.00116	CcSEcCtD
Methyl aminolevulinate—Nausea—Vincristine—kidney cancer	0.000798	0.00116	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—KRAS—kidney cancer	0.000796	0.0029	CbGpPWpGaD
Methyl aminolevulinate—Paraesthesia—Capecitabine—kidney cancer	0.000786	0.00115	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Paclitaxel—kidney cancer	0.000786	0.00115	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CDH1—kidney cancer	0.000776	0.00282	CbGpPWpGaD
Methyl aminolevulinate—Asthenia—Paclitaxel—kidney cancer	0.000766	0.00112	CcSEcCtD
Methyl aminolevulinate—Nausea—Gemcitabine—kidney cancer	0.000757	0.0011	CcSEcCtD
Methyl aminolevulinate—Fatigue—Capecitabine—kidney cancer	0.000755	0.0011	CcSEcCtD
Methyl aminolevulinate—Pruritus—Paclitaxel—kidney cancer	0.000755	0.0011	CcSEcCtD
Methyl aminolevulinate—Pain—Capecitabine—kidney cancer	0.000749	0.00109	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Doxorubicin—kidney cancer	0.000743	0.00108	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—PIK3CA—kidney cancer	0.000731	0.00266	CbGpPWpGaD
Methyl aminolevulinate—Dizziness—Paclitaxel—kidney cancer	0.000706	0.00103	CcSEcCtD
Methyl aminolevulinate—Urticaria—Capecitabine—kidney cancer	0.000696	0.00101	CcSEcCtD
Methyl aminolevulinate—Erythema—Doxorubicin—kidney cancer	0.000692	0.00101	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—RAF1—kidney cancer	0.000689	0.00251	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—RELA—kidney cancer	0.000686	0.0025	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—ERBB2—kidney cancer	0.000682	0.00248	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CD8A—kidney cancer	0.000681	0.00248	CbGpPWpGaD
Methyl aminolevulinate—Rash—Paclitaxel—kidney cancer	0.000673	0.000981	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—MTOR—kidney cancer	0.000673	0.00245	CbGpPWpGaD
Methyl aminolevulinate—Dermatitis—Paclitaxel—kidney cancer	0.000672	0.00098	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CD4—kidney cancer	0.000671	0.00244	CbGpPWpGaD
Methyl aminolevulinate—Headache—Paclitaxel—kidney cancer	0.000669	0.000975	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—RAF1—kidney cancer	0.000662	0.00241	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—RELA—kidney cancer	0.000659	0.0024	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—ERBB2—kidney cancer	0.000654	0.00238	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—MTOR—kidney cancer	0.000646	0.00235	CbGpPWpGaD
Methyl aminolevulinate—Hypersensitivity—Capecitabine—kidney cancer	0.000645	0.000941	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CD4—kidney cancer	0.000645	0.00235	CbGpPWpGaD
Methyl aminolevulinate—Nausea—Paclitaxel—kidney cancer	0.000634	0.000924	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CDKN1B—kidney cancer	0.000631	0.0023	CbGpPWpGaD
Methyl aminolevulinate—Asthenia—Capecitabine—kidney cancer	0.000628	0.000916	CcSEcCtD
Methyl aminolevulinate—Pruritus—Capecitabine—kidney cancer	0.00062	0.000903	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CDKN1B—kidney cancer	0.000606	0.00221	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—JUN—kidney cancer	0.000601	0.00219	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CTNNB1—kidney cancer	0.000596	0.00217	CbGpPWpGaD
Methyl aminolevulinate—Discomfort—Doxorubicin—kidney cancer	0.000582	0.000848	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—PTEN—kidney cancer	0.000581	0.00211	CbGpPWpGaD
Methyl aminolevulinate—Dizziness—Capecitabine—kidney cancer	0.000579	0.000844	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—TSC2—kidney cancer	0.000579	0.00211	CbGpPWpGaD
Methyl aminolevulinate—Oedema—Doxorubicin—kidney cancer	0.000565	0.000823	CcSEcCtD
Methyl aminolevulinate—Infection—Doxorubicin—kidney cancer	0.000561	0.000818	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—PTEN—kidney cancer	0.000558	0.00203	CbGpPWpGaD
Methyl aminolevulinate—Rash—Capecitabine—kidney cancer	0.000552	0.000805	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Capecitabine—kidney cancer	0.000552	0.000804	CcSEcCtD
Methyl aminolevulinate—Headache—Capecitabine—kidney cancer	0.000549	0.0008	CcSEcCtD
Methyl aminolevulinate—Nausea—Capecitabine—kidney cancer	0.00052	0.000759	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—KIT—kidney cancer	0.000511	0.00186	CbGpPWpGaD
Methyl aminolevulinate—Paraesthesia—Doxorubicin—kidney cancer	0.000507	0.000739	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—MAPK3—kidney cancer	0.000497	0.00181	CbGpPWpGaD
Methyl aminolevulinate—Fatigue—Doxorubicin—kidney cancer	0.000487	0.00071	CcSEcCtD
Methyl aminolevulinate—Pain—Doxorubicin—kidney cancer	0.000483	0.000704	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—MAPK1—kidney cancer	0.000473	0.00172	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CDH1—kidney cancer	0.00047	0.00171	CbGpPWpGaD
Methyl aminolevulinate—Urticaria—Doxorubicin—kidney cancer	0.000449	0.000654	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—KRAS—kidney cancer	0.000446	0.00162	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—KRAS—kidney cancer	0.000429	0.00156	CbGpPWpGaD
Methyl aminolevulinate—Hypersensitivity—Doxorubicin—kidney cancer	0.000416	0.000606	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—PIK3CA—kidney cancer	0.00041	0.00149	CbGpPWpGaD
Methyl aminolevulinate—Asthenia—Doxorubicin—kidney cancer	0.000405	0.000591	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—RAF1—kidney cancer	0.000401	0.00146	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—RELA—kidney cancer	0.000399	0.00145	CbGpPWpGaD
Methyl aminolevulinate—Pruritus—Doxorubicin—kidney cancer	0.000399	0.000582	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—ERBB2—kidney cancer	0.000397	0.00144	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—PIK3CA—kidney cancer	0.000394	0.00143	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—MTOR—kidney cancer	0.000392	0.00143	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CD4—kidney cancer	0.000391	0.00142	CbGpPWpGaD
Methyl aminolevulinate—Dizziness—Doxorubicin—kidney cancer	0.000373	0.000544	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—CDKN1B—kidney cancer	0.000368	0.00134	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—IL2—kidney cancer	0.00036	0.00131	CbGpPWpGaD
Methyl aminolevulinate—Rash—Doxorubicin—kidney cancer	0.000356	0.000519	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Doxorubicin—kidney cancer	0.000356	0.000519	CcSEcCtD
Methyl aminolevulinate—Headache—Doxorubicin—kidney cancer	0.000354	0.000516	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—JUN—kidney cancer	0.00035	0.00127	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CTNNB1—kidney cancer	0.000347	0.00126	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—PTEN—kidney cancer	0.000339	0.00123	CbGpPWpGaD
Methyl aminolevulinate—Nausea—Doxorubicin—kidney cancer	0.000335	0.000489	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—MAPK3—kidney cancer	0.000289	0.00105	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—MAPK1—kidney cancer	0.000275	0.001	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—KRAS—kidney cancer	0.00026	0.000946	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—PIK3CA—kidney cancer	0.000239	0.000869	CbGpPWpGaD
